Stockscreener 앱 받기
8.54
0.00%
0.00
시간 외 거래:
8.48
-0.06
-0.70%
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Investment Report: How much upside does Kyverna Therapeutics Inc have2026 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Levels Update: What is Kyverna Therapeutics Incs book value per share2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Kyverna Therapeutics (KYTX) CFO receives new stock options and RSU grant - Stock Titan
Kyverna (KYTX) CEO receives 350,000 options and 58,000 RSUs in equity grants - Stock Titan
Kyverna Therapeutics (KYTX) awards stock options and RSUs to officer Naji Gehchan - Stock Titan
What is Kyverna Therapeutics Incs book value per share2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN
KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year - TradingView
How Kyverna Therapeutics Inc. stock compares to growth peersWeekly Stock Report & Long Hold Capital Preservation Tips - Naître et grandir
Portfolio Recap: Is Kyverna Therapeutics Inc stock trending bullishBreakout Watch & Safe Entry Zone Tips - baoquankhu1.vn
Kyverna to present stiff person syndrome trial data at AAN meeting - Investing.com Australia
Kyverna secures up to $150M loan facility from Oxford Finance - MSN
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - Sahm
Kyverna Therapeutics Announces Presentations on Miv-cel Research at AAN Annual Meeting 2026 - Quiver Quantitative
New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan
Aug Fed Impact: What is the Moat Score of Kyverna Therapeutics IncWeekly Profit Recap & Verified Short-Term Trading Plans - baoquankhu1.vn
Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX) - Stock Titan
Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant - Stock Titan
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Biotech Kyverna lines up March talks at Leerink, Jefferies events - Stock Titan
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
P5002025 Year in Review & Long-Term Safe Return Strategies - mfd.ru
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Director at Kyverna Therapeutics (KYTX) granted options and RSUs - Stock Titan
Kyverna Therapeutics (KYTX) director Emany Sravan Kumar files Form 3 - Stock Titan
Is Kyverna Therapeutics Inc. undervalued by DCF analysisMarket Volume Report & AI Powered Trade Plan Recommendations - mfd.ru
Kyverna Therapeutics Strengthens Board With New Director Appointments - The Globe and Mail
Kyverna adds two directors as board prepares for commercial stage By Investing.com - Investing.com Canada
Beam Therapeutics Inc. announced that it expects to receive $500 million in funding - marketscreener.com
Kyverna Therapeutics appoints biotech leaders Sravan Emany and Andrew Miller to board of directors - marketscreener.com
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - Bitget
Biotech leaders join Kyverna Therapeutics (KYTX) board as Spiegelman exits - Stock Titan
KYTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KYTXKyverna Therapeutics Latest Stock News & Market Updates - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bain Capital Life Sciences discloses 5.4% Kyverna (KYTX) ownership stake - Stock Titan
Rubin-led Northpond funds show 6.1% Kyverna (KYTX) stake in 13G/A - Stock Titan
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - Yahoo Finance
What’s Kyverna Therapeutics Inc.’s historical returnOil Prices & Safe Investment Capital Preservation Plans - mfd.ru
Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat
What is the Moat Score of Kyverna Therapeutics IncMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Does Kyverna Therapeutics Inc. outperform in volatile marketsJuly 2025 EndofMonth & Verified Entry Point Signals - mfd.ru
Profit Review: Can Kyverna Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Report & Reliable Volume Spike Trade Alerts - mfd.ru
Kyverna Therapeutics (KYTX) CTO Mayobanex Pujols reports no share ownership on Form 3 - Stock Titan
Stock Recap: Is AIRT a defensive stockWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Myasthenia Gravis Market Forecast Indicates 10.4% CAGR Growth by 2034, Reports DelveInsight - Barchart.com
Aug Reactions: Can Kyverna Therapeutics Inc weather a recessionQuarterly Market Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Aug PostEarnings: Does Koninklijke Philips NV Depositary Receipt outperform in volatile marketsQuarterly Trade Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Income Plays: Can Kyverna Therapeutics Inc maintain sales growthJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Aug Momentum: How Kyverna Therapeutics Inc. stock performs after earningsEarnings Miss & Short-Term Trading Opportunity Alerts - mfd.ru
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer By Investing.com - Investing.com Nigeria
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing - TipRanks
Kyverna Therapeutics appoints Mayo Pujols as chief technology officer - Investing.com
1.20%
0.06%
자본화:
|
볼륨(24시간):